Stoke Therapeutics, Inc. (STOK) Comparison with companies in other sectors?

Stoke Therapeutics, Inc. has a share price of 54.60M. You can analyze Stoke Therapeutics, Inc. (STOK) competitors across different market sectors through stock heatmaps.

What are STOK's NET and operating margins?

Stoke Therapeutics, Inc. (STOK) operating margin is around 0.20, and net profit margin is approximately 0.26 as of the latest reports.

In what way does STOK's earnings per share (EPS) trend reflect its financial momentum?

Stoke Therapeutics, Inc. (STOK) EPS is 0.82 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Stoke Therapeutics, Inc. is 15.74, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Stoke Therapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Stoke Therapeutics, Inc. like P/E which is 14.86, P/B which is 2.13, and PEG which is 0.10. Compare them with sector averages to evaluate if the stock is priced fairly.

Stoke Therapeutics, Inc.

STOK•NASDAQ

Healthcare

Biotechnology

$12.91

$0.06(0.47%)

Stoke Therapeutics, Inc. (STOK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.82

P/E Ratio

15.74

ROE

0.19%

Net Margin

0.26%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$704.85M

Shares OutstandingTotal number of shares issued

$54.60M

Book Value/ShareNet worth per share

$6.82

Revenue/ShareAnnual revenue per share

$3.30

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.82

Net MarginNet income as percentage of revenue

26.33%

Operating MarginOperating income as percentage of revenue

20.03%

ROEReturn on shareholders' equity

19.08%

ROAReturn on total assets

12.36%

ROCEReturn on capital employed

10.56%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$1.20

Cash/ShareCash and equivalents per share

$6.18

FCF YieldFree cash flow as percentage of market cap

9.81%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for STOKFinancial Ratios Analysis details for STOK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for STOKSector Benchmarking details for STOK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Stoke Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Stoke Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Stoke Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Stoke Therapeutics, Inc.

For Stoke Therapeutics, Inc., essential financial indicators include EPS 0.82, PE 15.74, and ROE 0.19. These key ratios reveal insights into Stoke Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Stoke Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Stoke Therapeutics, Inc.

Metrics like Net Margin 26.33% and ROA 12.36% shed light on how well Stoke Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Stoke Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Stoke Therapeutics, Inc.

Using ratios such as P/B Ratio 2.13 and PEG Ratio 0.10, investors can assess whether Stoke Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Stoke Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Stoke Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $1.20, provide a snapshot of Stoke Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Stoke Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Stoke Therapeutics, Inc.

Investing in Stoke Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Stoke Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;